<DOC>
	<DOC>NCT02494349</DOC>
	<brief_summary>The purpose of this study is to investigate and compare the pharmacokinetic characteristics and safety/tolerability between JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg)and co-administration of Solifenacin and Tamsulosin between Solifenacin and Tamsulosin in healthy male volunteers.</brief_summary>
	<brief_title>The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.</brief_title>
	<detailed_description>A randomized, open-label, single dose, two-way crossover study.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>19~45 years healthy male Body weight is over 55kg, BMI measurement 18.0kg/m^2~ 27.0kg/m^2 Signed informed consent form from to participate voluntarily and to comply with the trial requirements. Researchers determined suitable volunteers through physical examination, laboratory tests History of clinically significant liver, kidneys, nervous system, immune system, respiratory, endocrine disorders or tumor or blood disorders, cardiovascular diseases, mental disorders (mood disorders, obsessivecompulsive disorder, etc.) Sitting SBP&gt;150mmHg or &lt;100mmHg, sitting DBP&gt;100mmHg or &lt;60mmHg, after 3 minutes break An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason. Have a gastrointestinal disease history that can affect drug absorption (Crohn's disease ulcers, etc) or surgery (except simple appendectomy or hernia surgery) History of drug abuse Positive urine drug screening Administrated investigational product in a previous clinical trial within 90 days of the first administration day in this study. Donated blood within 60 days prior to the first administration day in this study.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Î±1-blockers</keyword>
	<keyword>antimuscarinic agent</keyword>
</DOC>